Rigin
- Category
- Specialized Research
- Administration routes
- Topical
- Regulatory status
- Cosmetic ingredient
Rigin is a synthetic tetrapeptide (Gly-Gln-Pro-Arg) sold as an immune modulator for phagocytosis, cytokine balance, and wound healing. The case rests mostly on mechanism and animal data, human evidence is low confidence, and claims of antimalarial or antifungal action are speculative. Human safety data is largely absent, with a theoretical risk of overstimulated immunity in autoimmune disease. Not FDA-approved; supply is unregulated research-grade product.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Rigin is a naturally occurring four-amino-acid peptide first isolated in 1981 from human immunoglobulin G (IgG) — one of the main antibodies your immune system produces. It is released when IgG is broken down by enzymes, and it stimulates the immune system's ability to engulf and destroy pathogens (phagocytosis) at levels equal to tuftsin, another well-known immune peptide from the same antibody. In the skincare world, a modified form called palmitoyl tetrapeptide-7 (rigin with a fatty acid chain attached) has become one of the most widely used anti-aging ingredients, known for suppressing the inflammatory signals that accelerate skin aging. It is half of the Matrixyl 3000 complex.
How it works in the body
A tetrapeptide (Gly-Gln-Pro-Arg) that modulates immune function. It interacts with T lymphocytes and other immune cells to enhance proliferation and differentiation, supporting the adaptive immune response. It also has mild anti-inflammatory properties through modulation of cytokine profiles.
Research overview
Rigin activates the immune system primarily through lymphocytes (a type of white blood cell), distinguishing it from tuftsin, which works mainly through macrophages. It stimulates phagocytosis, enhances killer T-cell activity, and regulates inflammatory signaling molecules including IL-1, IL-6, and TNF. Its cosmetic derivative, palmitoyl tetrapeptide-7, works by suppressing IL-6 — a key driver of chronic, low-grade inflammation associated with aging (sometimes called 'inflammaging'). In small human trials, Matrixyl 3000 formulations containing palmitoyl tetrapeptide-7 showed up to 14% reduction in wrinkles, 8.8% improvement in skin elasticity, and 27.6% increase in dermal density at 4 weeks, with a 2024 multi-ingredient eye-cream study reporting about 55% higher ultrasound-assessed collagen density at 12 weeks; the individual peptide's contribution was not isolated. The immune research spans four decades with solid preclinical data, while the skincare evidence is moderate with small clinical trials. No clinical trials exist for systemic immune use in humans.
Who researches Rigin?
Commonly researched by
People exploring tissue repair and injury recovery
Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.
People researching immune system support
Studied for immune modulation, antiviral, or antimicrobial properties.
People researching inflammation management
Studied for anti-inflammatory effects across various conditions.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(5)
Rated by level of concern
Unknown systemic safety profile
HighPMID 11379040; PMID 41953401 / PMC13054063 (topical cosmetic scope only)
Limited long-term topical safety data
ModeratePMID 38932444 / PMC11208285; PMID 25817264
Contact dermatitis (topical palmitoyl tetrapeptide-7)
LowPMID 41953401 / PMC13054063 (cites CIR conclusion)
Skin irritation when combined with retinoids
TheoreticalNo primary source; mechanistic extrapolation
Potential immunostimulatory risk in autoimmune conditions
TheoreticalPMID 7309346; PMID 11379040
Interaction summary(7)
Rated by direction with this peptide
Immunosuppressants (ciclosporin, tacrolimus, mycophenolate, systemic corticosteroids)
CautionTheoreticalRigin's demonstrated enhancement of phagocytosis, and its analogs' enhancement of cell-mediated and humoral responses in mice, run pharmacodynamically opposite to intentional immunosuppression, so use alongside transplant or autoimmune regimens is mechanistically discouraged. Never studied in humans and no interaction has been observed.
PMID 7309346; PMID 11379040
Immune checkpoint inhibitors (anti-PD-1, anti-CTLA-4)
CautionTheoreticalAdding a general immunostimulant to checkpoint blockade is a plausible route to amplified immune-related adverse events, but this is pure mechanistic reasoning with zero published data for rigin in any species.
PMID 11379040 (immunostimulant activity only); no interaction data
Vaccines and vaccine adjuvants
SynergisticTheoreticalThe 2001 murine analog study reported improved humoral and cell-mediated responses and enhanced macrophage uptake of peptide-bearing liposomes, and the authors proposed the analogs as adjuvants in chemotherapy and as a prophylactic supplement to boost immune status. Extension of that to vaccine co-administration is an inference; no licensed vaccine has been co-administered with rigin.
PMID 11379040
Antimalarial drugs (chloroquine, artemisinin derivatives)
SynergisticTheoreticalProphylactic intravenous rigin analogs reduced parasitaemia and mortality in Plasmodium berghei-infected mice via host immune enhancement, a complementary rather than overlapping mechanism to schizonticidal drugs, and the authors suggested adjuvant use alongside chemotherapy. No actual combination experiment has been performed.
PMID 11379040
Tuftsin and other phagocytosis-stimulating peptides
SynergisticTheoreticalRigin's phagocytosis-stimulating activity was measured as equal to tuftsin's, and the 2001 study found hydrophobic rigin analogs act more through lymphocytes whereas tuftsin and its analog mainly activate polymorphonuclear leukocytes and macrophages, suggesting non-redundant but entirely untested combined activity.
PMID 7309346; PMID 11379040
Topical retinoids (tretinoin, adapalene, retinol)
CautionTheoreticalNo peptide-specific interaction is documented; the practical concern is additive irritation from retinoid-induced barrier disruption in layered topical routines, not a chemical or receptor-level conflict.
No primary source; formulation-level extrapolation
Topical exfoliating acids (AHA/BHA) and other barrier-disrupting actives
CautionTheoreticalIncreased penetration and reactivity in compromised skin is a general expectation for any layered cosmetic peptide; the human data for palmitoyl tetrapeptide-7 come from mild multi-active formulations with no reported adverse events and did not test acid co-application.
PMID 38932444 / PMC11208285; no interaction study
Known risks(5)
Contact dermatitis (topical palmitoyl tetrapeptide-7)
LowA repeat-insult patch test of a mixture containing 500 ppm palmitoyl tetrapeptide-7 in 52 subjects found no irritation or sensitization potential. This does not establish population rates of contact dermatitis or severe allergy.
Skin irritation when combined with retinoids
Low-ModerateIrritation rates for palmitoyl tetrapeptide-7 used with retinoids have not been established by the cited studies.
Unknown systemic safety profile
Unknown (no human data)Rigin has never been tested in human clinical trials for systemic (injectable or oral) administration. Its safety profile for systemic use is entirely unknown. Preclinical mouse studies of intravenous rigin reported no toxicity, but this does not substitute for formal human safety evaluation. The topical safety profile does not apply to systemic exposure.
Potential immunostimulatory risk in autoimmune conditions
Theoretical (no clinical data)Given rigin's immunostimulatory properties — enhancing phagocytosis, activating lymphocytes, modulating cytokine production — there is a theoretical risk that it could exacerbate autoimmune conditions if used systemically. Tuftsin (rigin's analog) has been studied in autoimmune encephalomyelitis models where timing of macrophage/microglial activation proved critical. Individuals with autoimmune disorders should exercise caution even with topical use.
Limited long-term topical safety data
LowWhile palmitoyl tetrapeptide-7 has been used in cosmetics for many years, comprehensive post-marketing surveillance data remains limited. No long-term (multi-year) safety studies of continuous topical use have been published. The CIR Expert Panel considers it safe for cosmetic use at current concentrations based on available data.
Drug interactions(4)
Topical retinoids (tretinoin, adapalene, tazarotene)
Co-application with retinoids increases skin irritation rates to 25-30% (vs 8-12% for palmitoyl tetrapeptide-7 alone). Recommend staggering application times or introducing gradually. No systemic interaction expected due to minimal absorption.
Topical corticosteroids
Concurrent use may mask early signs of peptide-induced irritation, potentially leading to more severe reactions upon steroid discontinuation. Use with caution and monitor skin response during tapering.
Immunosuppressive medications (systemic)
Theoretical interaction: immunosuppressants may alter inflammatory responses to rigin, though clinical data is limited due to minimal systemic absorption from topical application. For any hypothetical systemic rigin use, immunosuppressants would potentially counteract rigin's immunostimulatory effects.
Other topical active ingredients (AHAs, BHAs, vitamin C, niacinamide)
No clinically significant interactions reported. Palmitoyl tetrapeptide-7 is generally compatible with common skincare actives. However, combining multiple active ingredients may increase overall skin irritation risk in sensitive individuals.
Research & benefits
Evidence base
- Evidence Level
- Preclinical
- Total Studies
- 12
- Human Studies
- 3
Rigin has a modest but growing evidence base. For systemic immunomodulatory applications, evidence is entirely preclinical: in vitro phagocytosis assays, cytokine modulation studies in mouse macrophages and human monocytes, and in vivo malaria protection studies in mice. No clinical trials have evaluated systemic rigin administration in humans. For topical anti-aging use, palmitoyl tetrapeptide-7 has been tested in several small clinical studies as part of multi-ingredient formulations, showing reductions in wrinkles, improvements in elasticity, and increases in dermal density and collagen. However, no placebo-controlled RCT has isolated palmitoyl tetrapeptide-7 as the sole active ingredient. Safety data is favorable: HRIPT in 52 subjects showed no irritation or sensitization, and clinical studies report no adverse reactions at standard cosmetic concentrations (0.01-2%).
Researched for(7)
Rated by confidence in the evidence
Phagocytosis stimulation and innate immune enhancement
LowIn vitro and animal data show tuftsin-like phagocytic activity, no human studies conducted.
PMID 7309346; PMID 10691984; PMID 20629117
Cytokine modulation — IL-1, IL-6, and TNF regulation
SpeculativeIL-6 reduction claim comes from cosmetic industry data, no controlled studies confirm it.
PMID 34451799 / PMC8400021; PMID 39858482 / PMC11762834
Anti-inflammatory skin protection and collagen preservation
SpeculativeHuman studies used peptide blends only, individual contribution to skin protection unproven.
PMC8400021; PMID 25817264; PMID 38932444 / PMC11208285
Enhanced cell-mediated and humoral immune response via lymphocyte activation
LowMouse study found modified rigin analogs boosted immunity, native peptide untested in humans.
PMID 11379040
Anti-malarial protection (preclinical)
SpeculativeSingle mouse experiment reduced malaria severity using modified analogs, never replicated or tested in humans.
PMID 11379040
Wound healing support via VEGF and fibronectin induction
SpeculativeNo peer-reviewed study links this peptide to VEGF or fibronectin, claim traces to marketing.
PMID 39858482 / PMC11762834 (mechanism list omits VEGF/fibronectin); no primary source identified
Antifungal activity (synthetic analog library)
SpeculativeLab screen found synthetic analogs inhibit plant fungi, native rigin inactive, no human relevance shown.
PMID 40076526 / PMC11900302
Benefits(7)
Phagocytosis stimulation and innate immune enhancement
Veretennikova et al. 1981 (Int J Pept Protein Res, PMID 7309346) — Rigin stimulated phagocytosis of Staphylococcus aureus by rat blood leukocytes at levels equal to tuftsin. Rocchi et al. 1987 (Int J Pept Protein Res, PMID 3570666) — Of all tested peptides, only rigin enhanced the phagocytic capacity of mouse peritoneal macrophages to the same extent as tuftsin.
Cytokine modulation — IL-1, IL-6, and TNF regulation
Rocchi et al. 1991 (Int J Pept Protein Res, PMID 1869367) — Rigin and glycosylated tuftsin derivatives were evaluated for capacity to evoke release of IL-1 and TNF from mouse peritoneal macrophages and human monocytes, demonstrating dose-dependent cytokine modulation. Sederma/Croda proprietary data — Palmitoyl tetrapeptide-7 reduces basal and UV-induced IL-6 secretion in keratinocytes and fibroblasts, mimicking the cytokine-balancing effects of DHEA.
Anti-inflammatory skin protection and collagen preservation
Hahn et al. 2016 (Exp Ther Med) — Formulations containing palmitoyl peptides including palmitoyl tetrapeptide-7 reduced wrinkles by 14.07%, increased skin elasticity by 8.79%, and increased dermal density by 27.63% after 4 weeks in 20 female volunteers (ages 30-65). Yang et al. 2024 (Skin Res Technol, PMC11208285) — Eye cream containing palmitoyl tetrapeptide-7 showed 28.12% increase in skin hydration, 18.81% elasticity improvement, and 54.99% increase in ultrasound-assessed collagen density with the multi-ingredient cream after 12 weeks with no adverse reactions.
Enhanced cell-mediated and humoral immune response via lymphocyte activation
Dutta et al. 2001 (Int Immunopharmacol, PMID 11379040) — Hydrophobic rigin analogs (PR and CR) considerably improved both cell-mediated and humoral immune responses in mice. Unlike tuftsin which activates macrophages and polymorphonuclear leukocytes, rigin analogs manifest their response more through lymphocytes.
Anti-malarial protection (preclinical)
Dutta et al. 2001 (Int Immunopharmacol, PMID 11379040) — Hydrophobic rigin analogs administered prophylactically to mice produced substantial reduction in parasitaemia and mortality, increasing median survival time against Plasmodium berghei infection. The cholestanyl analog (CR) showed superior performance, likely due to better membrane interaction via steroid moiety.
Wound healing support via VEGF and fibronectin induction
Sederma/Croda proprietary studies — Palmitoyl tetrapeptide-7 induced marked expression of granulocyte chemotactic protein-2 (GCP-2), vascular endothelial growth factor (VEGF), and ephrin receptor genes. It also promotes synthesis of fibronectin, which supports tissue repair and cell adhesion, playing a pivotal role in wound healing processes.
Antifungal activity (synthetic analog library)
Porras et al. 2025 (Int J Mol Sci, PMC11900302) — A combinatorial library of synthetic rigin analogs identified unexpected antifungal drug leads. Tetrapeptide analog 18 (with morpholino group) demonstrated 79% radial growth inhibition of Botrytis cinerea at 500 mcM. Surprisingly, fully protected derivatives showed greater activity than free cationic peptides.
Key studies(8)
Rigin, another phagocytosis-stimulating tetrapeptide isolated from human IgG. Confirmations of a hypothesis
Original research (in vitro)In vitro phagocytosis assays with rat blood leukocytesVeretennikova NI, Chipens GI, Nikiforovich GV, Betinsh YR
International Journal of Peptide and Protein Research
1981
First identification and characterization of rigin (Gly-Gln-Pro-Arg) as a tuftsin-like tetrapeptide released by trypsin cleavage of human IgG H-chain at positions 341-344. Conformational analysis revealed spatial similarity to tuftsin. Synthesized rigin showed phagocytosis-stimulating activity equal to tuftsin against Staphylococcus aureus.
Synthesis and biological activity of tuftsin and rigin derivatives containing monosaccharides or monosaccharide derivatives
Original research (in vitro, synthetic chemistry)Multiple glycosylated peptide variants tested on mouse peritoneal macrophagesRocchi R, Biondi L, Cavaggion F, Filira F, Gobbo M, Dagan S, Fridkin M
International Journal of Peptide and Protein Research
1987
Of all tested peptides, only rigin enhanced the phagocytic capacity of mouse peritoneal macrophages to the same extent as tuftsin. Glycosylated derivatives showed modest activity. One glycosylated tuftsin variant displayed stronger receptor binding than tuftsin itself but failed to stimulate phagocytosis, revealing structure-activity distinctions between binding affinity and functional activation.
Glyco-tuftsin derivatives modulate interleukin-1 and tumor necrosis factor production
Original research (in vitro, cytokine modulation)Mouse peritoneal macrophages and human monocytesRocchi R, Biondi L, Filira F, Tzehoval E, Dagan S, Fridkin M
International Journal of Peptide and Protein Research
1991
Rigin (H-Gly-Gln-Pro-Arg-OH) and glycosylated tuftsin derivatives were evaluated for capacity to release IL-1 and TNF from mouse peritoneal macrophages and human monocytes. Several glycosylated derivatives modulated cytokine release in a dose-dependent manner. Established rigin's role in cytokine modulation pathways.
Characterization of a novel type VII beta-turn conformation for a bio-active tetrapeptide rigin: a synergy between theoretical and experimental results
Original research (structural biology, NMR/molecular dynamics)Single peptide characterizationAshish, Grover A, Kishore R
European Journal of Biochemistry
2000
First comprehensive structural characterization of rigin using 2D ROESY NMR and molecular dynamics. Identified an uncommonly observed type VII beta-turn conformation. Variable temperature NMR revealed that the preferred conformation is not stabilized by intramolecular hydrogen bonding. Primary structure rather than long-range interactions determines rigin's folding behavior.
Immunomodulatory potential of hydrophobic analogs of Rigin and their role in providing protection against Plasmodium berghei infection in mice
Original research (preclinical, in vivo)Multiple mouse cohorts100 mcg/0.5 mL/mouse/day IV for 2 days prophylacticallyDutta RC, Puri A, Anand N
International Immunopharmacology
2001
Hydrophobic rigin analogs (N-palmitoyl-amino-ethyl-rigin amide and N-cholestanyl-amino-ethyl-rigin amide) substantially improved cell-mediated and humoral immune responses in mice, acting through lymphocyte activation rather than macrophages. Prophylactic administration produced substantial reduction in parasitaemia and mortality against P. berghei infection, with increased median survival time. Proposed as potential adjuvants in chemotherapy and prophylactic immune boosters.
Folded conformation of an immunostimulating tetrapeptide rigin: high temperature molecular dynamics simulation study
Original research (computational/structural biology)83 low-energy conformers analyzedAshish A, Kishore R
Bioorganic & Medicinal Chemistry
2002
Quenched molecular dynamics revealed rigin adopts a distorted type III beta-turn across the central Gln-Pro segment, stabilized by a salt bridge (Gly H3N+...COO- Arg) rather than classical hydrogen bonding. Identified an unusual main-chain-to-side-chain hydrogen bond by glutamine forming a seven-membered ring motif. Findings are valuable for designing rigin analogs with enhanced biological activity.
Instrumental evaluation of anti-aging effects of cosmetic formulations containing palmitoyl peptides, Silybum marianum seed oil, vitamin E and other functional ingredients on aged human skin
Open-label clinical trial (human)20 female volunteers (ages 30-65)4 weeks, twice daily applicationHahn HJ, Jung HJ, Schrammek-Drusios MC, Lee SN, Kim JH, Kwon SB, An IS, An S, Ahn KJ
Experimental and Therapeutic Medicine
2016
Formulations containing palmitoyl peptides (including palmitoyl tetrapeptide-7) reduced wrinkles by 14.07%, increased skin elasticity by 8.79%, increased dermal density by 27.63%, increased skin brightness by 2.14%, and decreased erythema by 22.39% after 4 weeks. Measurements used 3D imaging, elasticity probing, ultrasonic scanning, and spectrophotometry. No abnormal responses reported.
Antifungal Peptides with Unexpected Structure from a Library of Synthetic Analogs of Host-Defense Peptide Rigin
Original research (synthetic chemistry, antifungal screening)Combinatorial library of rigin analogsPorras M, Hernandez D, Boto A
International Journal of Molecular Sciences
2025
Combinatorial library of synthetic rigin analogs identified unexpected antifungal leads. Morpholino-substituted tetrapeptide analog showed 79% radial growth inhibition of Botrytis cinerea at 500 mcM. Surprisingly, fully protected (hydrophobic) analogs were more active than free cationic peptides, challenging conventional assumptions about antimicrobial peptide design.
Regulation & availability
Why researchers look at it
A 2024 study of a multi-ingredient eye cream containing palmitoyl tetrapeptide-7 reported about 55% higher ultrasound-assessed collagen density at 12 weeks, with earlier trials demonstrating up to 14% wrinkle reduction and 27.6% increase in dermal density at 4 weeks. Suppresses IL-6, a pro-inflammatory cytokine linked to age-related sarcopenia, cardiovascular disease, and neurodegeneration. Four decades of preclinical immunomodulatory research remain unexplored in human trials, but could open the door to systemic anti-inflammaging applications.
- FDA status
- NOT FDA-APPROVED. Rigin (H-Gly-Gln-Pro-Arg-OH) has no FDA approval for any therapeutic indication. It has not undergone FDA-regulated clinical trials for systemic use. The peptide is classified as a research compound. Its derivative palmitoyl tetrapeptide-7 is regulated as a cosmetic ingredient (not a drug) when used in skincare products. The Cosmetic Ingredient Review (CIR) Expert Panel has assessed palmitoyl oligopeptides including palmitoyl tetrapeptide-7 and determined them safe for cosmetic use at current concentrations. Palmitoyl tetrapeptide-7 is listed in the INCI (International Nomenclature of Cosmetic Ingredients) database. There are no Investigational New Drug (IND) applications, no active clinical trials listed on ClinicalTrials.gov, and no New Drug Applications (NDAs) on file with the FDA for rigin or palmitoyl tetrapeptide-7 as a drug product.
- WADA status
- Native rigin is not individually named, but its use as an unapproved pharmacological substance appears to fall under WADA S0 and should not be described as permitted. The cosmetic derivative palmitoyl tetrapeptide-7 requires separate assessment; cosmetic availability does not establish anti-doping clearance.
- Prescribability
- No — rigin is not an FDA-approved drug and is not available as a prescription medication for systemic immunomodulatory or anti-aging use. No physician can write a prescription for rigin as a therapeutic agent. There are no compounding pharmacy formulations approved for rigin. Individuals seeking its immunomodulatory or anti-inflammatory benefits would need to use cosmetic products containing palmitoyl tetrapeptide-7 topically or participate in research studies.
- Availability
- Rigin is not available as a prescription therapeutic. Its cosmetic form is palmitoyl tetrapeptide-7 (Pal-GQPR, CAS 221227-05-0), also sold combined with palmitoyl tripeptide-1 as Matrixyl 3000. Palmitoyl tetrapeptide-7 is a common ingredient in anti-aging creams, serums, and eye treatments from numerous skincare brands at concentrations of 0.01-2%. These products are available without prescription from retailers worldwide. There are no prescription formulations, compounding pharmacy preparations, or clinic-dispensed versions of rigin for systemic therapeutic use.
International status
EU
Not approved
US
Not FDA-approved
Worldwide
No regulatory approval in any jurisdiction
Regulatory timeline(11)
- 1981-04Veretennikova, Chipens, Nikiforovich, and Betinsh publish the discovery of rigin (Gly-Gln-Pro-Arg) as a phagocytosis-stimulating tetrapeptide from human IgG H-chain (Int J Pept Protein Res, PMID 7309346).
- 1987-02Rocchi et al. publish synthesis and biological activity of tuftsin and rigin derivatives with monosaccharides, confirming rigin equals tuftsin in macrophage phagocytosis enhancement (PMID 3570666).
- 1991-03Rocchi et al. demonstrate rigin and glycosylated tuftsin derivatives modulate IL-1 and TNF production from macrophages and human monocytes (PMID 1869367).
- 2000-03Ashish et al. characterize rigin's novel type VII beta-turn conformation using NMR and molecular dynamics (Eur J Biochem, PMID 10691984).
- 2001-05Dutta et al. demonstrate hydrophobic rigin analogs enhance immune responses and protect against malaria in mice (Int Immunopharmacol, PMID 11379040).
- 2002-12Ashish and Kishore publish high-temperature molecular dynamics study revealing rigin's salt-bridge-stabilized conformation (Bioorg Med Chem, PMID 12413862).
- ~2005Sederma (Croda) develops and commercializes palmitoyl tetrapeptide-7 under the trade name Rigin for cosmetic anti-aging applications. Combined with palmitoyl tripeptide-1 as Matrixyl 3000.
- 2014CIR Expert Panel publishes safety assessment of palmitoyl oligopeptides including palmitoyl tetrapeptide-7, determining them safe for cosmetic use.
- 2016-06Hahn et al. publish clinical evaluation of palmitoyl peptide formulations showing wrinkle reduction, elasticity improvement, and dermal density increase in 20 female volunteers (Exp Ther Med).
- 2024-06Yang et al. publish 12-week clinical evaluation of anti-aging eye cream containing palmitoyl tetrapeptide-7 showing 54.99% increase in ultrasound-assessed collagen density with the multi-ingredient cream (Skin Res Technol, PMC11208285).
- 2025-02Porras et al. publish discovery of antifungal peptides from combinatorial library of rigin analogs (Int J Mol Sci, PMC11900302).
Sources & FAQs
Research sources(14)
- Veretennikova et al. 1981 — Rigin discovery, phagocytosis-stimulating tetrapeptide from IgG
- Rocchi et al. 1987 — Tuftsin and rigin derivatives with monosaccharides, macrophage phagocytosis
- Rocchi et al. 1991 — Glyco-tuftsin derivatives, IL-1 and TNF modulation
- Ashish et al. 2000 — Type VII beta-turn conformation of rigin, NMR characterization
- Dutta et al. 2001 — Hydrophobic rigin analogs, immunomodulation, P. berghei protection
- Ashish & Kishore 2002 — Rigin molecular dynamics, salt-bridge conformation
- Hahn et al. 2016 — Anti-aging effects of palmitoyl peptide formulations on human skin
- Yang et al. 2024 — Anti-aging eye cream with palmitoyl tetrapeptide-7, clinical evaluation
- Porras et al. 2025 — Antifungal rigin analogs, combinatorial peptide library
- CIR Expert Panel — Safety assessment of palmitoyl oligopeptides in cosmetics
- Cosmetic Ingredients Guide — Palmitoyl tetrapeptide-7 (Rigin) monograph
- PubChem — Rigin compound entry (CID 127555)
- Wikipedia — Tetrapeptide (rigin entry)
- WADA 2026 Prohibited List
Frequently asked questions(5)
What is the difference between rigin and palmitoyl tetrapeptide-7?
Rigin is the native tetrapeptide (H-Gly-Gln-Pro-Arg-OH) derived from the IgG heavy chain. Palmitoyl tetrapeptide-7 (Pal-GQPR) is a synthetic derivative in which palmitic acid (a 16-carbon fatty acid) is conjugated to rigin's N-terminus to make it more lipophilic, enhancing skin penetration and affinity for cell membranes. They share the same core tetrapeptide sequence and similar biological activities (phagocytosis stimulation, IL-6 suppression), but palmitoyl tetrapeptide-7 is specifically designed and optimized for topical cosmetic applications. Sederma (Croda) markets its palmitoyl tetrapeptide-7 cosmetic ingredient under the trade name 'Rigin,' which can create confusion. The native peptide is a research compound; the palmitoylated version is a widely used cosmetic ingredient.
How does rigin compare to tuftsin?
Both rigin (Gly-Gln-Pro-Arg) and tuftsin (Thr-Lys-Pro-Arg) are immunostimulatory tetrapeptides derived from the heavy chain of human IgG, sharing the C-terminal Pro-Arg dipeptide critical for biological activity. Both stimulate phagocytosis at comparable levels. However, they differ in their primary immune cell targets: tuftsin acts mainly through macrophages and polymorphonuclear leukocytes, while rigin and its hydrophobic analogs manifest their immune response more through lymphocyte activation. Rigin corresponds to IgG residues 341-344; tuftsin to residues 289-292.
Is rigin effective for anti-aging when applied topically?
The evidence is promising but indirect. Palmitoyl tetrapeptide-7 (the cosmetic form of rigin) has been shown to reduce IL-6 secretion (a key driver of inflammaging), stimulate collagen synthesis, and improve wrinkle depth, elasticity, and dermal density in small clinical studies. However, most studies test multi-ingredient formulations, so isolating palmitoyl tetrapeptide-7's individual contribution is difficult. No large placebo-controlled RCT has tested it as a single active ingredient. For topical anti-aging purposes, it is considered a credible ingredient with a plausible mechanism of action, but the clinical evidence is limited.
Can rigin be used systemically for immune enhancement?
Not currently for human use. While preclinical studies show rigin and its analogs enhance immune responses and protect against infection in mice, there are no human clinical trials for systemic rigin administration. The native peptide is available only as a research compound. Any systemic use would be experimental and unregulated. The preclinical data is encouraging — particularly for potential applications in infectious disease, immune deficiency, and as a chemotherapy adjuvant — but human safety and efficacy remain unestablished.
What is Matrixyl 3000 and how does rigin relate to it?
Matrixyl 3000 is a commercial cosmetic complex developed by Sederma (Croda) that combines palmitoyl tetrapeptide-7 (the rigin derivative) with palmitoyl tripeptide-1. Palmitoyl tripeptide-1 stimulates collagen synthesis directly, while palmitoyl tetrapeptide-7 reduces inflammation and protects the extracellular matrix from degradation. Together, they provide complementary anti-aging mechanisms. Matrixyl 3000 is one of the most widely used peptide complexes in the cosmetics industry and is found in many premium anti-aging skincare products.